Q2 Earnings Forecast for VTYX Issued By HC Wainwright

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – Research analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for Ventyx Biosciences in a research note issued on Wednesday, November 5th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.56) for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Ventyx Biosciences’ Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.35) EPS, FY2027 earnings at ($2.24) EPS, FY2028 earnings at ($1.99) EPS and FY2029 earnings at ($1.57) EPS.

Ventyx Biosciences (NASDAQ:VTYX) last announced its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.13.

Several other equities analysts also recently issued reports on the stock. Wells Fargo & Company increased their price objective on shares of Ventyx Biosciences from $11.00 to $14.00 and gave the company an “overweight” rating in a report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Ventyx Biosciences in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Canaccord Genuity Group lifted their price objective on Ventyx Biosciences from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday. Finally, Oppenheimer increased their target price on Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a report on Monday, October 27th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock opened at $8.77 on Friday. The stock has a market capitalization of $625.38 million, a P/E ratio of -5.85 and a beta of 1.23. The company’s fifty day moving average price is $4.21 and its 200 day moving average price is $2.90. Ventyx Biosciences has a 1 year low of $0.78 and a 1 year high of $9.50.

Institutional Trading of Ventyx Biosciences

Several large investors have recently bought and sold shares of VTYX. Wealth Enhancement Advisory Services LLC purchased a new position in Ventyx Biosciences in the 1st quarter worth approximately $28,000. Hudson Bay Capital Management LP purchased a new position in Ventyx Biosciences during the second quarter worth approximately $34,000. Pallas Capital Advisors LLC acquired a new position in Ventyx Biosciences during the second quarter worth $38,000. Engineers Gate Manager LP acquired a new position in Ventyx Biosciences during the second quarter worth $42,000. Finally, Jump Financial LLC acquired a new stake in shares of Ventyx Biosciences in the 2nd quarter worth $53,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.